X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Catalent Celebrates Opening Of Second Shanghai Facility To Optimize Global And Local Clinical Supply Solution

Content Team by Content Team
17th April 2019
in Manufacturing, Middle East and South Asia, Press Statements
Global And Local Clinical Supply Solution

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Catalent Pharma Solutions, a global leader in clinical supply services, announced the completion of its new, 30,000-square-foot clinical supply facility in Shanghai, China. The event was marked with an official opening ceremony at the site on April 10.

The facility, located outside of the free trade zone (FTZ) in Tangzhen, is near to both Catalent’s existing Waigaoqiao FTZ site and China’s Zhangjiang Pharma Valley area. Together, Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally. It is expected to employ up to 100 people and offers comprehensive clinical supply services including FastChain® demand-led supply, secondary packaging, clinical storage and local distribution, as well as clinical returns and destruction services.

At the ribbon-cutting ceremony to officially open the site, Catalent executives welcomed local government officials and local and international pharma customers. Guests were accompanied on a site tour, and the opening ceremony also featured a traditional Chinese lion dance and a symbolic light display to reflect the bright future of the site’s foundations.

“We are delighted to have already engaged customers for services in Tangzhen,” commented Roel de Nobel, Vice President, Global Operations, Catalent Clinical Supply Services. He added, “Having facilities both inside and outside the FTZ in China affords customers flexibility, convenience and streamlined logistics in support of the growing number of trials being conducted in the region.”

The Tangzhen opening follows recent investments in Singapore and Japan, strengthening Catalent’s capabilities to support clinical trials in Asia and beyond.

With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.

For further information on Catalent’s Clinical Supply Services business visit https://www.clinical.catalent.com

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.

Previous Post

Celularity Selects Cryoport Temperature Controlled Logistics Solutions

Next Post

Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility

Related Posts

FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
active pharmaceutical ingredients supply chain
Drug Development

Future of Active Pharmaceutical Ingredients Supply

26th September 2025
pharmaceutical excipients for new therapies
Drug Development

Advances in Pharmaceutical Excipients for New Therapies

26th September 2025
Next Post
Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility

Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In